Research programme: Streptococcus vaccine and antibody therapeutics - Valneva

Drug Profile

Research programme: Streptococcus vaccine and antibody therapeutics - Valneva

Alternative Names: Group A Streptococcus antibodies - Intercell; Group A Streptococcus antibodies - Valneva; Group A Streptococcus vaccine - Intercell; Group A Streptococcus vaccine - Valneva; Group B Streptococcus antibodies - Intercell; Group B Streptococcus antibodies - Valneva

Latest Information Update: 01 Jul 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intercell
  • Developer Valneva
  • Class Monoclonal antibodies; Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Streptococcal infections

Most Recent Events

  • 01 Jul 2013 No development reported - Preclinical for Streptococcal infections in Austria (Parenteral)
  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 01 Sep 2010 Preclinical development is ongoing with Intercell
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top